One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format
Executive Summary
The single-page format could serve as a template as FDA tries to simplify patient information that accompanies prescription drugs.
You may also be interested in...
Opioid Abuse-Deterrent Formulations Could Become Prerequisite To Approval
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recommends against approval of Zogenix’s Zohydro ER as it seeks safer formulations and stricter REMS for all extended-release/long-acting opioids.
Oral Contraceptive Labeling Likely To Become More Graphic
FDA is nearing completion of guidance on labeling for combined oral contraceptives with an eye toward improving communication with more visual presentations rather than relying on prose.
Mandatory Training For Opioid Prescribers Remains Stuck On Drawing Board
FDA and DEA continued to negotiate through the Office of National Drug Control Policy on a viable option for a mandatory prescriber education program, which would be a large burden for whichever agency gets the job.